Results
toxicity, death, cancers except disease characteristics for GIST
DISEASE PROGRESSION, DISEASE
From 17 April 2014 to 25 July 2018, a total of 251 patients were screened and 206 patients were enrolled in the study across the ATC (Demographic and baseline characteristicsPopulation is the efficacy evaluable population.Values are for primary and expansion cohorts combined for all cancers except disease characteristics for GIST, LGG and ASI, which include the primary analysis cohort.Patients received oral dabrafenib (150 mg twice daily) and oral trametinib (2 mg once daily) on a continuous dosing schedule until unacceptable toxicity, disease progression or death. Across all cohorts, the median duration of exposure to dabrafenib and trametinib was 12.5 months (range, 1–82 months) and 12.0 months (range, 1–84 months), respectively. Two-thirds of the patients received dabrafenib (66%) and trametinib (65%) for more than 6 months. The median daily dose of dabrafenib and trametinib was 282.1 mg (range, 16.9–315.5 mg) and 1.9 mg (range, 0.6–2 mg), respectively (a daily dose of 450 mg dabrafenib was administered in eight patients). A total of 111 patients (54%) died; 31% withdrew from the study due to the sponsor’s decision to terminate the study; and 13% withdrew consent. The most common reason for study treatment discontinuation was progressive disease (dabrafenib: 60%; trametinib: 59%) (Extended Data Fig. 